The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.

2.

EVP Beats Cisplatin for Resectable MIBC

3.

Men With Prostate Cancer Experience Less Hot Flashes When Using an Affordable Drug.

4.

Formaldehyde releasers found in common personal care products used especially by Black and Latina women

5.

Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot